Valeant, Ackman Poised To Go Hard In $46B Allergan Fight
With its rejection of a $46 billion joint bid from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman, Allergan Inc. on Monday officially opened the door to a contentious buyout...To view the full article, register now.
Already a subscriber? Click here to view full article